Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies

. 2024 Nov ; 11 (6) : e200328. [epub] 20241023

Jazyk angličtina Země Spojené státy americké Médium print-electronic

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/pmid39442037

BACKGROUND AND OBJECTIVES: Women with multiple sclerosis (MS) are at risk of disease reactivation in the early postpartum period. Ocrelizumab (OCR) is an anti-CD20 therapy highly effective at reducing MS disease activity. Data remain limited regarding use of disease-modifying therapies (DMTs), including OCR, and disease activity during peripregnancy periods. METHODS: We performed a retrospective cohort study using data from the MSBase Registry including pregnancies conceived after December 31, 2010, from women aged 18 years and older, with relapsing-remitting MS or clinically isolated syndrome. Women were classified by preconception exposure to DMTs, including OCR, rituximab (RTX), natalizumab (NAT), stratified into active (NAT-A; continued ≥28 weeks of gestation, restarted ≤1 month postpartum) or conservative (NAT-C; continued ≤4 weeks of gestation, restarted >1 month postpartum) strategies, dimethyl fumarate (DMF) or low-efficacy DMTs (interferon-beta, glatiramer acetate). Annualized relapse rates (ARRs) were calculated for 12-month prepregnancy, pregnancy, and 6-month postpartum periods. RESULTS: A total of 2,009 live births from 1,744 women were analyzed, including 73 live births from 69 women treated with preconception OCR. For OCR, no within-pregnancy relapse was observed and 3 women (4.1%) experienced 1 relapse in the postpartum period (ARR 0.09 [95% CI 0.02-0.27]). For NAT-A, 3 (3.7%) of 82 women relapsed during pregnancy (0.05 [0.01-0.15]) and 4 (4.9%) relapsed during postpartum (0.10 [0.03-0.26]). However, for NAT-C, 13 (15.9%) of 82 women relapsed within pregnancy (0.32 [0.20-0.51]) and 25 (30.5%) relapsed during postpartum (0.74 [0.50-1.06]). In the low-efficacy DMT group, 101 (7.6%) of 1,329 women experienced within-pregnancy relapse (0.12 [0.10-0.14]), followed by an increase in postpartum relapse activity with 234 women (17.6%) relapsing (0.43 [0.38-0.48]). This was similarly seen in the DMF group with 13 (7.9%) of 164 women experiencing within-pregnancy relapse (0.12 [0.06-0.20]) and 25 (15.2%) of 164 relapsing postpartum (0.39 [0.26-0.57]). Our RTX cohort had 0 of 24 women experiencing within-pregnancy relapse and 3 (12.5%) of 24 experiencing postpartum relapse. DISCUSSION: Women treated with OCR or NAT-A were observed to have low relapse rates during pregnancy and postpartum. NAT-C was associated with increased risk of relapses. There was no within-pregnancy relapse in our RTX cohort, although we caution overinterpretation due to our sample size. An effective DMT strategy with a favorable safety profile for the mother and infant should be discussed and implemented well in advance of planning a family. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that for women with relapsing-remitting MS or clinically isolated syndrome who become pregnant, ocrelizumab, rituximab, and natalizumab (continued ≥28 weeks of gestation and restarted ≤1 month postpartum) were associated with reduced risk of relapses, compared with other therapeutic strategies.

Zobrazit více v PubMed

Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med. 1998;339(5):285-291. doi: 10.1056/NEJM199807303390501 PubMed DOI

Hughes SE, Spelman T, Gray OM, et al. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler. 2014;20(6):739-746. doi: 10.1177/1352458513507816 PubMed DOI

Yeh WZ, Widyastuti PA, Van der Walt A, et al. Natalizumab, fingolimod, and dimethyl fumarate use and pregnancy-related relapse and disability in women with multiple sclerosis. Neurology. 2021;96(24):e2989-e3002. doi: 10.1212/WNL.0000000000012084 PubMed DOI PMC

Alroughani R, Alowayesh MS, Ahmed SF, Behbehani R, Al-Hashel J. Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. Neurology. 2018;90(10):e840-e846. doi: 10.1212/WNL.0000000000005065 PubMed DOI

Portaccio E, Ghezzi A, Hakiki B, et al. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. J Neurol Neurosurg Psychiatry. 2014;85(8):845-850. doi: 10.1136/jnnp-2013-306054 PubMed DOI

Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus interferon beta-1a in relapsing multiple sclerosis. N Engl J Med. 2017;376(3):221-234. doi: 10.1056/NEJMoa1601277 PubMed DOI

Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017;376(3):209-220. doi: 10.1056/NEJMoa1606468 PubMed DOI

Hauser SL, Kappos L, Arnold DL, et al. Five years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension. Neurology. 2020;95(13):e1854-e1867. doi: 10.1212/WNL.0000000000010376 PubMed DOI PMC

Wolinsky JS, Arnold DL, Brochet B, et al. Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2020;19(12):998-1009. doi: 10.1016/S1474-4422(20)30342-2 PubMed DOI

Hellwig K, Oreja-Guevara C, Vukusic S, et al. Pregnancy and Infant Outcomes in Women Receiving Ocrelizumab for the Treatment of Multiple Sclerosis: Analysis of the Largest Available Outcomes Database. MSMilan2023; 2023.

Das G, Damotte V, Gelfand JM, et al. Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm. 2018;5(3):e453. doi: 10.1212/NXI.0000000000000453 PubMed DOI PMC

Kümpfel T, Thiel S, Meinl I, et al. Anti-CD20 therapies and pregnancy in neuroimmunologic disorders: a cohort study from Germany. Neurol Neuroimmunol Neuroinflamm. 2021;8(1):e913. doi: 10.1212/NXI.0000000000000913 PubMed DOI PMC

Razaz N, Piehl F, Frisell T, Langer-Gould AM, McKay KA, Fink K. Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab. Neurol Neuroimmunol Neuroinflamm. 2020;7(6):e903. doi: 10.1212/NXI.0000000000000903 PubMed DOI PMC

Smith JB, Hellwig K, Fink K, et al. Rituximab, MS, and pregnancy. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e734. doi: 10.1212/NXI.0000000000000734 PubMed DOI PMC

Anderson A, Rowles W, Poole S, et al. Anti-CD20 monoclonal antibody therapy in postpartum women with neurological conditions. Ann Clin Translational Neurol. 2023;10(11):2053-2064. doi: 10.1002/acn3.51893 PubMed DOI PMC

Demortiere S, Maarouf A, Rico A, et al. Disease evolution in women with highly active MS who suspended natalizumab during pregnancy vs rituximab/ocrelizumab before conception. Neurol Neuroimmunol Neuroinflamm. 2023;10(5):e200161. doi: 10.1212/NXI.0000000000200161 PubMed DOI PMC

Krysko KM, Dobson R, Alroughani R, et al. Family planning considerations in people with multiple sclerosis. Lancet Neurol. 2023;22(4):350-366. doi: 10.1016/S1474-4422(22)00426-4 PubMed DOI

Kalincik T, Butzkueven H. The MSBase registry: informing clinical practice. Mult Scler. 2019;25(14):1828-1834. doi: 10.1177/1352458519848965 PubMed DOI

Jokubaitis VG, Skibina O, Alroughani R, et al. The MSBase pregnancy, neonatal outcomes, and women's health registry. Ther Adv Neurol Disord. 2021;14:17562864211009104. doi: 10.1177/17562864211009104 PubMed DOI PMC

Whittam DH, Tallantyre EC, Jolles S, et al. Rituximab in neurological disease: principles, evidence and practice. Pract Neurol. 2019;19(1):5-20. doi: 10.1136/practneurol-2018-001899 PubMed DOI

Hellwig K, Tokic M, Thiel S, et al. Multiple sclerosis disease activity and disability following discontinuation of natalizumab for pregnancy. JAMA Netw Open. 2022;5(1):e2144750. doi: 10.1001/jamanetworkopen.2021.44750 PubMed DOI PMC

R Core Team. R: A Language and Environment for Statistical Computing [online]. R Foundation for Statistical Computing; 2019. R-project.org/

Wickham H, Averick M, Bryan J, et al. Welcome to the tidyverse. J Open Source Softw. 2019;4(43):1686. doi: 10.21105/joss.01686 DOI

Kappos L, Traboulsee A, Li DKB, et al. Ocrelizumab exposure in relapsing–remitting multiple sclerosis: 10-year analysis of the phase 2 randomized clinical trial and its extension. J Neurol. 2024;271:642-657. doi: 10.1007/s00415-023-11943-4 PubMed DOI PMC

Baker D, Pryce G, James LK, Marta M, Schmierer K. The ocrelizumab phase II extension trial suggests the potential to improve the risk: benefit balance in multiple sclerosis. Mult Scler Relat Disord. 2020;44:102279. doi: 10.1016/j.msard.2020.102279 PubMed DOI

Honce JM, Nair KV, Sillau S, et al. Rituximab vs placebo induction prior to glatiramer acetate monotherapy in multiple sclerosis. Neurology. 2019;92(7):e723–e732. doi: 10.1212/WNL.0000000000006916 PubMed DOI PMC

Bove R, Hellwig K, Pasquarelli N, et al. Ocrelizumab during pregnancy and lactation: rationale and design of the MINORE and SOPRANINO studies in women with MS and their infants. Mult Scler Relat Disord. 2022;64:103963. doi: 10.1016/j.msard.2022.103963 PubMed DOI

U.S. Food and Drug Administration. Ocrevus - Full Prescribing Information [online]; 2022. Accessed January 6, 2024. accessdata.fda.gov/drugsatfda_docs/label/2022/761053s029s030lbl.pdf

European Medicines Agency. Ocrevus - Summary of Product Characteristics [online]; 2022. Accessed January 6, 2024. ema.europa.eu/en/documents/product-information/ocrevus-epar-product-information_en.pdf

Dobson R, Rog D, Ovadia C, et al. Anti-CD20 therapies in pregnancy and breast feeding: a review and ABN guidelines. Pract Neurol. 2023;23(1):6-14. doi: 10.1136/pn-2022-003426 PubMed DOI

Chey SY, Kermode AG. Pregnancy outcome following exposure to ocrelizumab in multiple sclerosis. Mult Scler J Exp Transl Clin. 2022;8(1):20552173221085737. doi: 10.1177/20552173221085737 PubMed DOI PMC

Gitman V, Stavropoulos A, Saenz V, Pasquarelli N, Zecevic D, Devonshire V. Pregnancy outcomes of women with multiple sclerosis treated with ocrelizumab in Canada: a descriptive analysis of real-world data. Mult Scler Relat Disord. 2022;62:103792. doi: 10.1016/j.msard.2022.103792 PubMed DOI

Langer-Gould A, Li BH, Smith JB, Xu S. Multiple sclerosis, rituximab, hypogammaglobulinemia, and risk of infections. Neurology(R) neuroimmunology & neuroinflammation 2024;11(3):e200211. doi: 10.1212/NXI.0000000000200211 PubMed DOI PMC

Hauser S, Kappos L, Montalban X, et al. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. 9th Joint ECTRIMS-ACTRIMS Meeting (MSMilan2023). 2023.

Landi D, Bovis F, Grimaldi A, et al. Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2022:jnnp-2022-329657. doi: 10.1136/jnnp-2022-329657 PubMed DOI

Portaccio E, Moiola L, Martinelli V, et al. Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: maternal risks. Neurology. 2018;90(10):e832-e839. doi: 10.1212/WNL.0000000000005068 PubMed DOI

Triplett JD, Vijayan S, Rajanayagam S, Tuch P, Kermode AG. Pregnancy outcomes amongst multiple sclerosis females with third trimester natalizumab use. Mult Scler Relat Disord. 2020;40:101961. doi: 10.1016/j.msard.2020.101961 PubMed DOI

Portaccio E, Pastò L, Razzolini L, et al. Natalizumab treatment and pregnancy in multiple sclerosis: a reappraisal of maternal and infant outcomes after 6 years. Mult Scler. 2022;28(13):2137-2141. doi: 10.1177/13524585221079598 PubMed DOI

Ebrahimi N, Herbstritt S, Gold R, Amezcua L, Koren G, Hellwig K. Pregnancy and fetal outcomes following natalizumab exposure in pregnancy. A prospective, controlled observational study. Mult Scler 2015;21(2):198-205. doi: 10.1177/1352458514546790 PubMed DOI

Haghikia A, Langer-Gould A, Rellensmann G, et al. Natalizumab use during the third trimester of pregnancy. JAMA Neurol. 2014;71(7):891-895. doi: 10.1001/jamaneurol.2014.209 PubMed DOI

Thiel S, Litvin N, Haben S, Gold R, Hellwig K. Disease activity and neonatal outcomes after exposure to natalizumab throughout pregnancy. J Neurol Neurosurg Psychiatry. 2024;95(6):561-570. doi: 10.1136/jnnp-2023-332804 PubMed DOI PMC

Friend S, Richman S, Bloomgren G, Cristiano LM, Wenten M. Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study. BMC Neurol. 2016;16(1):150. doi: 10.1186/s12883-016-0674-4 PubMed DOI PMC

Dobson R, Dassan P, Roberts M, Giovannoni G, Nelson-Piercy C, Brex PA. UK consensus on pregnancy in multiple sclerosis: “Association of British Neurologists” guidelines. Pract Neurol. 2019;19(2):106-114. doi: 10.1136/practneurol-2018-002060 PubMed DOI

Ciplea AI, Langer-Gould A, de Vries A, et al. Monoclonal antibody treatment during pregnancy and/or lactation in women with MS or neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflamm. 2020;7(4):e723. doi: 10.1212/NXI.0000000000000723 PubMed DOI PMC

Proschmann U, Haase R, Inojosa H, Akgün K, Ziemssen T. Drug and neurofilament levels in serum and breastmilk of women with multiple sclerosis exposed to natalizumab during pregnancy and lactation. Front Immunol. 2021;12:715195. doi: 10.3389/fimmu.2021.715195 PubMed DOI PMC

Landi D, Ragonese P, Prosperini L, et al. Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry. 2018;89(12):1272-1278. doi: 10.1136/jnnp-2018-318468 PubMed DOI

Kaplan TB, Bove R, Galetta K, Healy B, Chitnis C, Houtchens M. Effect of pregnancy loss on MS disease activity. J Neurol Sci. 2019;397:58-60. doi: 10.1016/j.jns.2018.12.028 PubMed DOI

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace

Nahrávání dat ...